Psychoactive substances with chemical structures or pharmacological profiles that are
similar to traditional drugs of abuse continue to emerge on the recreational drug market …

The growing demand for improved pain treatments together with expanding legalization of,
and access to, cannabinoids, cannabis, and cannabis-based medicines has intensified the …

Background Monitoring the use of psychoactive substances and substance-related
problems in the population allows for the assessment of prevalence and associated health …

The pharmacological interventions available for individuals in the early stages of psychosis
are extremely limited. For those at clinical high risk for psychosis, there is no licensed …

This Phase II study evaluated analgesia, abuse liability, and cognitive performance of
hydromorphone and oral delta-9-tetrahydrocannabinol (THC; dronabinol) using a within …

The rapid structural evolution and emergence of novel synthetic cannabinoid receptor
agonists (SCRAs) in the recreational market remains a key public health concern. Despite …

Cannabinoids have emerged as compelling candidates for medicinal applications, notably
following the recent approval of non-psychoactive cannabidiol (CBD) as a medicine. This …

Background Quantitative (eg increasing recreational cannabinoid use) and qualitative (eg
increasing availability and use of synthetic cannabinoids and cannabis preparations with …

Synthetic cannabinoids (SCs) have become established drugs of abuse. They play an
increasing role in drug therapy, where abstinence control testing is required. Differentiation …

Psychoactive drugs are substances which when ingested alter mental functioning including
but not limited to changes in thinking, awareness, emotions and regulation. Throughout …